Expression of Bcl-2 and Bax in human gastric cancer tissue
Komatsu, K.; Suzuki, S.; Ohara, S.; Asaki, S.; Toyota, T.; Suzuki, H.
Nihon Rinsho. Japanese Journal of Clinical Medicine 54(7): 1929-1934
1996
ISSN/ISBN: 0047-1852 PMID: 8741690 Document Number: 466624
Deregulation of bcl-2 may function as a survival mechanism in cancer cells, predisposed to cell death. Aberrant Bcl-2 expression is a frequent occurrence in chronic atrophic gastritis, gastric epithelial dysplasia and gastric cancer. Inhibition of apoptosis through Bcl-2 expression appears to be specifically associated with promotion of gastric adenocarcinoma. In addition, loss of heterozygosity of the bcl-2 gene is a common event in well-differentiated adenocarcinoma, whereas overexpression of bcl-2 gene is observed in poorly differentiated adenocarcinoma. Bax, a homologue of Bcl-2, counters the death repressor activity of Bcl-2. In our study Bax immunostaining in gastric cancer tissue is not significantly correlated with tumor histology. Possible gene therapy using bax gene is discussed.